evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimers disease
Generally, the reconstitution process entails drawing a measure of bacteriostatic water into a syringe and then introducing that water to the peptide powder
Protocol 3: fat loss and body recomposition (2-3 peptides) Goal: Maximize fat loss while preserving or building lean mass Peptides: Semaglutide : Start 0.25mg weekly, titrate to 1-2.4mg weekly over 8-16 weeks BPC-157 : 250mcg twice daily (protects gut health during GLP-1 use) Optional third: Ipamorelin 100mcg twice daily (supports lean mass preservation) Why this works: Semaglutide provides powerful appetite suppression and improved insulin sensitivity for fat loss
A 43-amino acid synthetic peptide modeled after thymosin beta-4.- Reported to regulate actin dynamics via its LKKTETQ sequence, thereby influencing cellular migration and motility.- May also elevate microRNA-146a, which suppresses inflammatory pathways involving IRAK1 and TRAF6.- Preclinical studies point toward roles in wound contraction, tissue vascularization, and cardiac resilience under stress
